Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neurim Pharmaceuticals (1991) Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, indicating that the pending work is distributed across separate examination assignments rather than concentrated in one unit.
MARTIN, KEVIN STEPHEN is the busiest examiner, with 1 pending matter. Because that figure is below the portfolio total, another examiner also handles a pending matter. Practitioners should therefore track responses by examiner and art unit, while preserving technology-specific prosecution context for each case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.0% | +20.7% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18802285 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | MARTIN, KEVIN STEPHEN | — |
| 18390481 | METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERS | YOUNG, MICAH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18802285 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | MARTIN, KEVIN STEPHEN | 1624 | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18390481 | METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERS | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | — | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeurim Pharmaceuticals (1991) Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Kevin Stephen Martin has the most, with 1 of Neurim Pharmaceuticals (1991) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.